Device Week – April 25, 2016
This article was originally published in The Gray Sheet
On this week's podcast, The Gray Sheet team talks about renewed TAVR patent battles, hearing aid regulations, the most frequent citation in FDA QSR device warning letters, actions in Congress, Califf's priorities, criticisms of FDA's approach to cybersecurity and an FDA orthopedics panel vote.
You may also be interested in...
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.